AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.
Company Info
Recent News
AbbVie scooped up immunology player Apogee Therapeutics for nearly $11 billion in one of the year’s top deals to-date, while Sanofi made a big play to survive its upcoming Dupixent patent cliff; FDA uncertainty continues as the agency changes direction on gene therapies by uniQure and REGENXBIO;…
Fierce Biotech reports AbbVie is acquiring Apogee Therapeutics for $10.9B to gain control of a late-phase eczema drug candidate that could compete with Lilly, Regeneron, and Sanofi.
AbbVie agreed to acquire Apogee Therapeutics for $10.9B to gain access to its long-acting inflammation and immunology drug candidates, including Apogee's IL-13 / TSLP / OX40L pipeline.
Leadership Team
Chairman and Chief Executive Officer
Careers & Job Openings